Opportunity Information: Apply for PA 14 094
Apply for PA 14 094
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "HIV Infection of the Central Nervous System (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Feb 11, 2014 and posted on Feb 11, 2014.
- Applicants must submit their applications by Jan 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments State governments Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Special district governments For profit organizations other than small businesses Native American tribal governments (Federally recognized) Independent school districts Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses County governments Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH grant opportunity "HIV Infection of the Central Nervous System (R01)" (Funding Opportunity Number PA 14-094) supported research aimed at understanding how HIV-1 affects the brain and nervous system and how those effects can be treated or prevented. The central scientific focus is HIV-1 Associated Neurocognitive Disorders (HAND), a spectrum of neurobehavioral and neurological problems that can persist even in the era of effective antiretroviral therapy. The announcement sought projects that dig into the underlying disease mechanisms in the central nervous system (CNS), including how HIV enters and persists in CNS-related tissues, how infection and immune responses drive neural injury, and why cognitive and behavioral impairments emerge or continue over time. Alongside mechanism-focused work, the FOA also emphasized identifying therapeutic strategies, meaning applicants could propose interventions or approaches intended to prevent CNS injury, lessen neurological and cognitive symptoms, or improve long-term outcomes for people living with HIV.
The FOA was broad in the kinds of research it would consider, spanning both basic and translational science. Basic research could include cellular and molecular studies of HIV neuropathogenesis, host immune and inflammatory pathways, viral reservoirs in CNS compartments, and interactions among neurons, glia, and infiltrating immune cells. Translational research could include development or testing of candidate therapeutic strategies, biomarkers that track CNS injury or repair, neuroimaging or other measurement tools that connect biological changes to cognitive outcomes, and approaches that bridge laboratory findings to clinical application. The announcement explicitly noted interest in work conducted in both domestic and international settings, reflecting the reality that HIV burden, co-infections, treatment access, and comorbidities vary globally and can shape CNS outcomes in different ways.
Applications were submitted under the NIH R01 mechanism, which is the standard NIH research project grant intended for well-defined, hypothesis-driven projects. While the FOA encouraged multidisciplinary teams and collaborative alliances, it did not require them. In practice, that meant single-investigator projects were welcome, but projects that integrate expertise across neuroscience, virology, immunology, neuropsychology, clinical medicine, bioinformatics, and related fields would also fit well, especially given the complexity of HAND and CNS infection. The funding instrument type was a grant, and the opportunity was categorized as discretionary.
Eligibility was intentionally expansive. A wide range of applicant organizations could apply, including public and private institutions of higher education, nonprofits (including 501(c)(3) and certain nonprofits without 501(c)(3) status), for-profit organizations (including small businesses and other for-profits), and numerous government entities (state, county, city/township, special districts, independent school districts, and certain housing authorities). The announcement also included multiple categories of institutions serving specific populations, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs). Importantly, non-U.S. entities were eligible to apply, non-U.S. components of U.S. organizations were eligible, and foreign components (as defined by NIH policy) were allowed, reinforcing the FOA's openness to international and multinational research efforts. There was no cost-sharing or matching requirement.
From an administrative standpoint, the opportunity was issued by the National Institutes of Health and tied to multiple CFDA program areas that reflect the cross-cutting nature of CNS HIV research, including mental health research, alcohol research programs, drug abuse and addiction research, neurosciences and neurological disorders, allergy and infectious diseases, and microbiology and infectious diseases. The FOA was posted on February 11, 2014, and ultimately closed on January 7, 2017, with an archive date of February 7, 2017. The official announcement and details were hosted on the NIH grants site (linked in the source information), and NIH's Office of Extramural Research webmaster contacts were provided for access or technical issues.
Overall, this FOA was designed for investigators seeking to explain, at a mechanistic level, how HIV-1 causes or contributes to cognitive, behavioral, and neurological impairment through its effects in the CNS, and to translate that understanding into plausible prevention or treatment strategies for HAND. It prioritized scientifically rigorous studies that could clarify disease pathways, identify actionable therapeutic targets, and improve the clinical outlook for people living with HIV who experience ongoing neurocognitive complications.
Frequently Asked Questions (FAQs): NIH "HIV Infection of the Central Nervous System (R01)" (PA 14-094)
What is the NIH grant opportunity "HIV Infection of the Central Nervous System (R01)" (PA 14-094)?
It is an NIH Funding Opportunity Announcement (FOA) that supported research focused on how HIV-1 affects the brain and nervous system (the central nervous system, or CNS), why neurological and cognitive problems can occur or persist, and how those outcomes might be treated or prevented. The FOA used the NIH R01 research project grant mechanism.
What scientific problem did this FOA focus on?
The central focus was HIV-1 Associated Neurocognitive Disorders (HAND), a spectrum of neurobehavioral and neurological problems that can continue even in the era of effective antiretroviral therapy. The FOA emphasized mechanistic studies of CNS disease processes and work that could inform prevention or treatment strategies.
What is HAND in the context of this funding opportunity?
HAND refers to a range of cognitive, behavioral, and neurological impairments associated with HIV-1 infection. In this FOA, HAND was treated as a major clinical and scientific challenge because these impairments can persist over time, including among people receiving effective antiretroviral therapy.
What kinds of research questions were encouraged about HIV in the CNS?
The FOA encouraged projects that examine underlying disease mechanisms in the CNS, including how HIV enters and persists in CNS-related tissues, how infection and immune responses contribute to neural injury, and why cognitive and behavioral impairments develop or remain over time.
Did the FOA support treatment or prevention research, or only basic science?
It supported both. Alongside mechanism-focused work, the FOA emphasized identifying therapeutic strategies. Applicants could propose interventions or approaches intended to prevent CNS injury, lessen neurological and cognitive symptoms, or improve long-term outcomes for people living with HIV.
What is the balance between basic and translational research in this FOA?
The FOA was broad and included both basic and translational science. Basic research could focus on cellular and molecular mechanisms of HIV neuropathogenesis, while translational research could include development or testing of candidate therapeutic strategies and tools that connect biological changes to cognitive outcomes.
What are examples of basic research topics that fit this FOA?
Examples mentioned include cellular and molecular studies of HIV neuropathogenesis, host immune and inflammatory pathways, viral reservoirs in CNS compartments, and interactions among neurons, glia, and infiltrating immune cells.
What are examples of translational research topics that fit this FOA?
Examples mentioned include development or testing of candidate therapeutic strategies, biomarkers that track CNS injury or repair, neuroimaging or other measurement tools linking biological changes to cognitive outcomes, and approaches that bridge laboratory findings to clinical application.
Were international or non-U.S. research efforts allowed?
Yes. The FOA explicitly noted interest in work conducted in both domestic and international settings. Non-U.S. entities were eligible to apply, non-U.S. components of U.S. organizations were eligible, and foreign components (as defined by NIH policy) were allowed.
Why did the FOA encourage research in diverse global settings?
The FOA reflected that HIV burden, co-infections, treatment access, and comorbidities vary globally, and these differences can shape CNS outcomes in different ways.
What funding mechanism was used for applications?
Applications were submitted under the NIH R01 mechanism, which is the standard NIH research project grant intended for well-defined, hypothesis-driven projects.
Were multidisciplinary teams required?
No. The FOA encouraged multidisciplinary teams and collaborative alliances, but did not require them. Single-investigator projects were welcome, and collaborative projects spanning multiple disciplines were also a good fit.
What types of expertise were considered relevant for projects under this FOA?
The FOA described the topic area as complex and indicated that projects integrating expertise across areas such as neuroscience, virology, immunology, neuropsychology, clinical medicine, and bioinformatics could fit well.
What kinds of organizations were eligible to apply?
Eligibility was expansive and included public and private institutions of higher education, nonprofits (including 501(c)(3) and certain nonprofits without 501(c)(3) status), for-profit organizations (including small businesses and other for-profits), and multiple government entities (such as state, county, city/township, special districts, independent school districts, and certain housing authorities).
Were institutions serving specific populations included in the eligible applicants?
Yes. The FOA listed several categories of institutions serving specific populations, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs), and related categories.
Was cost-sharing or matching required?
No. The FOA stated there was no cost-sharing or matching requirement.
What type of funding instrument and funding category was this?
The funding instrument type was a grant, and the opportunity was categorized as discretionary.
Which agency issued this opportunity?
This opportunity was issued by the National Institutes of Health (NIH).
What program areas (CFDA areas) were associated with this FOA?
The FOA was tied to multiple CFDA program areas reflecting the cross-cutting nature of CNS HIV research, including mental health research, alcohol research programs, drug abuse and addiction research, neurosciences and neurological disorders, allergy and infectious diseases, and microbiology and infectious diseases.
When was the FOA posted, and when did it close?
The FOA was posted on February 11, 2014. It ultimately closed on January 7, 2017, with an archive date of February 7, 2017.
Where were the official announcement and details hosted?
The official announcement and details were hosted on the NIH grants site (as referenced in the source information for this opportunity).
Who was listed for access or technical issues related to the FOA posting?
NIH's Office of Extramural Research webmaster contacts were provided for access or technical issues.
What overall outcomes did this FOA aim to support?
It aimed to support scientifically rigorous studies that clarify disease pathways in the CNS, identify actionable therapeutic targets, and improve the clinical outlook for people living with HIV who experience ongoing neurocognitive complications.
Browse more opportunities from the same category: Education Health
Next opportunity: Eradication of HIV 1 from Central Nervous System Reservoirs (R01)
Previous opportunity: U.S. Speaker and Specialist Program for India
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 094
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 094) also looked into and applied for these:
| Funding Opportunity |
|---|
| Eradication of HIV 1 from Central Nervous System Reservoirs (R01) Apply for PA 14 095 Funding Number: PA 14 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization Apply for RFA CA 14 002 Funding Number: RFA CA 14 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| NIDA Avant Garde Award Program for HIV/AIDS and Drug Use Research (DP1) Apply for RFA DA 15 004 Funding Number: RFA DA 15 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Software and Analysis Methods for Biomedical Big Data in Targeted Areas of High Need (U01) Apply for RFA HG 14 020 Funding Number: RFA HG 14 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R21) Apply for PAR 14 013 Funding Number: PAR 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R21) Apply for PA 14 113 Funding Number: PA 14 113 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R01) Apply for PA 14 112 Funding Number: PA 14 112 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21) Apply for PAR 14 105 Funding Number: PAR 14 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03) Apply for PAR 14 104 Funding Number: PAR 14 104 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01) Apply for PAR 14 106 Funding Number: PAR 14 106 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Additional Research Training Slots for NIDA Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PAR 14 115 Funding Number: PAR 14 115 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) Apply for PAR 14 116 Funding Number: PAR 14 116 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Accelerating Improvements in the HIV Care Continuum (R01) Apply for PA 14 132 Funding Number: PA 14 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) Apply for PA 14 135 Funding Number: PA 14 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) Apply for PA 14 136 Funding Number: PA 14 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) Apply for PA 14 137 Funding Number: PA 14 137 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R21) Apply for PA 14 141 Funding Number: PA 14 141 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Community Partnerships to Advance Research (CPAR) (R01) Apply for PA 14 142 Funding Number: PA 14 142 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R15) Apply for PA 14 140 Funding Number: PA 14 140 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Additional Research Training Positions for NIAAA , NIDA , or NCI Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PA 14 146 Funding Number: PA 14 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 094", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.